Gilead Sciences (GILD) Construction in Progress (2010 - 2025)
Gilead Sciences' (GILD) quarterly Construction in Progress came in at $745.0 million in Q4 2025, up 48.7% YoY from $501.0 million in Q4 2024, and up 48.7% on a QoQ basis from $501.0 million in Q4 2024.
Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends
Gilead Sciences (GILD) has 16 years of Construction in Progress data on file, last reported at $745.0 million in Q4 2025.
- Quarterly Construction in Progress rose 48.7% year-over-year to $745.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $745.0 million (up 48.7% YoY) and the FY2025 annual result came in at $745.0 million, up 48.7% from the prior year.
- Construction in Progress grew to $745.0 million in Q4 2025, from $501.0 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $1.1 billion in Q4 2021 to a low of $501.0 million in Q4 2024.
- A 5-year average of $736.6 million and a median of $719.0 million in 2022 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2022 — Construction in Progress tumbled 31.98% — and 2025, when it jumped 48.7%.
- Tracing GILD's Construction in Progress over 5 years: stood at $1.1 billion in 2021, then plunged by 31.98% to $719.0 million in 2022, then retreated by 8.07% to $661.0 million in 2023, then retreated by 24.21% to $501.0 million in 2024, then jumped by 48.7% to $745.0 million in 2025.
- The last three Construction in Progress figures came in at $745.0 million (Q4 2025), $501.0 million (Q4 2024), and $661.0 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | - |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | - |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 745.00 Mn |
| Dec 31, 2024 | 501.00 Mn |
| Dec 31, 2023 | 661.00 Mn |
| Dec 31, 2022 | 719.00 Mn |
| Dec 31, 2021 | 1.06 Bn |
| Dec 31, 2020 | 856.00 Mn |
| Dec 31, 2019 | 723.00 Mn |
| Dec 31, 2018 | 1.19 Bn |
| Dec 31, 2017 | 690.00 Mn |
| Dec 31, 2016 | 641.00 Mn |
| Dec 31, 2015 | 554.00 Mn |
| Dec 31, 2014 | 411.00 Mn |
| Dec 31, 2013 | 129.00 Mn |
| Dec 31, 2012 | 216.43 Mn |
| Dec 31, 2011 | 60.75 Mn |
| Dec 31, 2010 | 82.33 Mn |